Literature DB >> 12796790

Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.

G Souillet1, N Guffon, I Maire, M Pujol, P Taylor, F Sevin, N Bleyzac, C Mulier, A Durin, K Kebaili, C Galambrun, Y Bertrand, R Froissart, C Dorche, L Gebuhrer, C Garin, J Berard, P Guibaud.   

Abstract

Over the last 15 years, we have performed a total of 30 haematopoietic stem cell transplants on 27 children suffering from Hurler's syndrome. These children were of median age 11 months at the time of diagnosis and 25 months at the time of transplantation. The phenotype was severe in 21 cases (78%). The donor was familial in 13 cases: nine genotypically identical, one phenotypically identical father and three HLA-mismatched donors. Unrelated donors were selected in 17 cases: four phenotypically identical and 13 with 1-4 HLA mismatches. The conditioning regimen generally consisted of busulphan 600 mg/m(2) plus cyclophosphamide (Endoxan) 260 mg/kg and cyclosporin with methotrexate for GvHD prophylaxis. Rabbit anti-thymocyte globulin (Thymoglobuline) was given for all unrelated or familial mismatched transplantations. The median nucleated cell dose infused was 6.00 x 10(8) TNC/kg. No bone marrow (apart from one) was T cell depleted. For first transplants, engraftment was observed in 23/27 patients (pts) (85%). Primary graft failure was observed in 4/27 patients (16%), two were retransplanted from an unrelated donor, one with success. Four patients have died. The primary cause of death was infection in three cases (TRM : 11%) and disease progression in one case, after primary graft failure. Of the 23 living patients, two have disease progression after graft failure and 21 (78%) have functional grafts with a favourable long-term outcome after a median follow-up of 4.7 years, having either full or mixed chimaerism. Among surviving patients with functional grafts, 13 (62%) were transplanted from unrelated donors of whom 10 (77 %) had HLA disparities. There was a remarkably low incidence of GvHD. In our experience, haematopoietic stem cell transplantation using an HLA-matched familial donor or an HLA-matched or -mismatched unrelated donor without T cell depletion or irradiation can achieve a favourable outcome in Hurler's syndrome, with improved cognitive function, but with a limited effect on the corneas and skeleton.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796790     DOI: 10.1038/sj.bmt.1704105

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  74 in total

1.  Carotid intima-media thickness is increased in patients with mucopolysaccharidoses.

Authors:  Raymond Y Wang; Kelly K Covault; Eileen M Halcrow; Audrey J Gardner; Xiaoling Cao; Robert L Newcomb; Richard D Dauben; Anthony C Chang
Journal:  Mol Genet Metab       Date:  2011-09-10       Impact factor: 4.797

Review 2.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 3.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 4.  Innovative therapy for Classic Galactosemia - tale of two HTS.

Authors:  M Tang; S I Odejinmi; H Vankayalapati; K J Wierenga; K Lai
Journal:  Mol Genet Metab       Date:  2011-10-01       Impact factor: 4.797

5.  Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.

Authors:  Shih-Hsin Kan; Mika Aoyagi-Scharber; Steven Q Le; Jon Vincelette; Kazuhiro Ohmi; Sherry Bullens; Daniel J Wendt; Terri M Christianson; Pascale M N Tiger; Jillian R Brown; Roger Lawrence; Bryan K Yip; John Holtzinger; Anil Bagri; Danielle Crippen-Harmon; Kristen N Vondrak; Zhi Chen; Chuck M Hague; Josh C Woloszynek; Diana S Cheung; Katherine A Webster; Evan G Adintori; Melanie J Lo; Wesley Wong; Paul A Fitzpatrick; Jonathan H LeBowitz; Brett E Crawford; Stuart Bunting; Patricia I Dickson; Elizabeth F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

6.  Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

7.  Prevalence and development of orthopaedic symptoms in the dutch hurler patient population after haematopoietic stem cell transplantation.

Authors:  F J Stoop; M C Kruyt; M H van der Linden; R J B Sakkers; P M van Hasselt; R M C Castelein
Journal:  JIMD Rep       Date:  2012-09-19

Review 8.  Mucopolysaccharidoses: overview of neuroimaging manifestations.

Authors:  Manal Nicolas-Jilwan; Moeenaldeen AlSayed
Journal:  Pediatr Radiol       Date:  2018-05-11

9.  Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.

Authors:  Daren Wang; Wei Zhang; Theodosia A Kalfa; Gregory Grabowski; Stella Davies; Punam Malik; Dao Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-10       Impact factor: 11.205

10.  Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents.

Authors:  Hiromasa Yabe; Hiroyasu Inoue; Masae Matsumoto; Satoshi Hamanoue; Aiko Hiroi; Takashi Koike; Masahiro Sako; Mitsuhiro Fujiwara; Yasunori Ueda; Etsuko Maruya; Hiroh Saji; Shunichi Kato; Miharu Yabe
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.